(Q37781993)

23 August 2017

title

Probiotics and prebiotics: clinical effects in allergic disease (English)

1 reference

23 August 2017

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733491

21 June 2024

2

Sampo J Lahtinen

1 reference

23 August 2017

1

Mimi L. K. Tang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733491

21 June 2024

3

Robert J. Boyle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733491

21 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20733491

21 June 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/10.1097/MOP.0b013e32833d9728

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Current Opinion in Pediatrics

21 June 2024

published in

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

626-634

1 reference

The effect of infections on susceptibility to autoimmune and allergic diseases

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study

21 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects

21 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing

21 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

The intestinal microflora in allergic Estonian and Swedish 2-year-old children

21 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Allergy development and the intestinal microflora during the first year of life

21 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants

21 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

21 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effect of maternal consumption of lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates

21 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics

21 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics in the management of atopic eczema

21 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics: a novel approach in the management of food allergy

21 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effects of probiotics on atopic dermatitis: a randomised controlled trial

21 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial.

21 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis.

21 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy

21 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Is the effect of probiotics on atopic dermatitis confined to food sensitized children?

21 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial

21 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effect of probiotic Lactobacillus strains in children with atopic dermatitis

21 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention

21 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome

21 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis

21 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years

21 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotic bacteria in the management of atopic disease: underscoring the importance of viability

21 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials

21 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study.

21 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants.

21 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial

21 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats

21 June 2024

30

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects

21 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

The acquisition of tolerance toward cow's milk through probiotic supplementation: a randomized, controlled trial

21 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics have a different immunomodulatory potential in vitro versus ex vivo upon oral administration in children with food allergy

21 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite.

21 June 2024

34

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Treatment of perennial allergic rhinitis with lactic acid bacteria

21 June 2024

35

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Bacillus clausii effects in children with allergic rhinitis

21 June 2024

36

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Clinical efficacy of halophilic lactic acid bacterium Tetragenococcus halophilus Th221 from soy sauce moromi for perennial allergic rhinitis

21 June 2024

37

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Specific probiotics alleviate allergic rhinitis during the birch pollen season

21 June 2024

38

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial

21 June 2024

40

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effect of milk fermented with Lactobacillus acidophilus strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial

21 June 2024

41

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study

21 June 2024

42

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study

21 June 2024

43

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis

21 June 2024

44

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study.

21 June 2024

45

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Immune and clinical impact of Lactobacillus acidophilus on asthma.

21 June 2024

46

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis

21 June 2024

47

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial

21 June 2024

48

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotic supplementation in the first 6 months of life in at risk Asian infants - effects on eczema and atopic sensitization at the age of 1 year

21 June 2024

49

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial

21 June 2024

50

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation.

21 June 2024

51

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial

21 June 2024

52

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Specific probiotics in enhancing maturation of IgA responses in formula-fed infants

21 June 2024

53

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial

21 June 2024

54

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial

21 June 2024

55

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study

21 June 2024

57

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial.

21 June 2024

58

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

The effects of selected probiotic strains on the development of eczema (the PandA study).

21 June 2024

59

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics during weaning reduce the incidence of eczema.

21 June 2024

60

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

21 June 2024

61

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Early markers of allergic disease in a primary prevention study using probiotics: 2.5-year follow-up phase

21 June 2024

62

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant

21 June 2024

63

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection.

21 June 2024

64

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial.

21 June 2024

65

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

A polymorphism in CD14 modifies the effect of farm milk consumption on allergic diseases and CD14 gene expression

21 June 2024

66

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life

21 June 2024

67

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age.

21 June 2024

68

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

Term infants fed formula supplemented with selected blends of prebiotics grow normally and have soft stools similar to those reported for breast-fed infants

21 June 2024

69

1 reference

https://api.crossref.org/works/10.1097/MOP.0B013E32833D9728

21 June 2024

Identifiers

1 reference

23 August 2017

1 reference